Haentjens-Verbeke K, Dufour P, Vinatier D, Bernardi C, Fonteyne G, Monnier J C, Mannessier L
Service de Gynécologie-Obstétrique, CHRU de Lille.
J Gynecol Obstet Biol Reprod (Paris). 1993;22(4):393-7.
A review of the literature concerning the very rare anti-PP1Pk isoimmunisation with a personal case.
Anti-PP1k antibody gives rise to the high risk of abortion in the first and the second trimester (in a different series the risk is 50-70%). A 19-year-old patient who had this antibody was helped by a plasmaphoresis repeatedly between the 6th and the 25th week of pregnancy. Cordocentesis was carried out to estimate fetal haemoglobin from the 25th week onwards. A set caesarean section was carried out at 36 weeks because of intrauterine growth retardation and the development of fetal anaemia.
The authors suggest research based on the known immunohaematological factors concerned with this isoimmunisation and on the main treatments available (plasmaphoresis, cordocentesis, and delivery at a set time).
Until now there have been very few cases and only four similar cases to ours have been reported in the literature. That is why it is so difficult to suggest a well defined strategy for treating these patients.
结合一个病例对关于极为罕见的抗PP1Pk同种免疫的文献进行综述。
抗PP1k抗体在妊娠早期和中期会引发流产的高风险（在不同系列研究中，风险为50 - 70%）。一名携带该抗体的19岁患者在妊娠第6周至第25周期间多次接受血浆置换治疗。从第25周起进行脐血穿刺以评估胎儿血红蛋白水平。由于胎儿宫内生长受限和胎儿贫血的发展，在孕36周时进行了择期剖宫产。
作者建议基于与这种同种免疫相关的已知免疫血液学因素以及现有的主要治疗方法（血浆置换、脐血穿刺和择期分娩）开展研究。
到目前为止，此类病例非常少，文献中仅报道了4例与我们的病例相似的情况。这就是为何很难提出明确的治疗这些患者的策略。
